Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Peter Rossing"'
Autor:
Lesley A, Inker, Nwamaka D, Eneanya, Josef, Coresh, Hocine, Tighiouart, Dan, Wang, Yingying, Sang, Deidra C, Crews, Alessandro, Doria, Michelle M, Estrella, Marc, Froissart, Morgan E, Grams, Tom, Greene, Anders, Grubb, Vilmundur, Gudnason, Orlando M, Gutiérrez, Roberto, Kalil, Amy B, Karger, Michael, Mauer, Gerjan, Navis, Robert G, Nelson, Emilio D, Poggio, Roger, Rodby, Peter, Rossing, Andrew D, Rule, Elizabeth, Selvin, Jesse C, Seegmiller, Michael G, Shlipak, Vicente E, Torres, Wei, Yang, Shoshana H, Ballew, Sara J, Couture, Neil R, Powe, Andrew S, Levey
Publikováno v:
The New England journal of medicine, vol. 385, no. 19, pp. 1737-1749
Inker, L A, Eneanya, N D, Coresh, J, Tighiouart, H, Wang, D, Sang, Y, Crews, D C, Doria, A, Estrella, M M, Froissart, M, Grams, M E, Greene, T, Grubb, A, Gudnason, V, Gutierrez, O M, Kalil, R, Karger, A B, Mauer, M, Navis, G, Nelson, R G, Poggio, E D, Rodby, R, Rossing, P, Rule, A D, Selvin, E, Seegmiller, J C, Shlipak, M G, Torres, V E, Yang, W, Ballew, S H, Couture, S J, Powe, N R, Levey, A S & Chronic Kidney Dis Epidemiology Co 2021, ' New Creatinine-and Cystatin C-Based Equations to Estimate GFR without Race ', New England Journal of Medicine, vol. 385, pp. 1737-1749 . https://doi.org/10.1056/NEJMoa2102953
The New England journal of medicine, vol 385, iss 19
New England Journal of Medicine, 385(19), 1737-1749. MASSACHUSETTS MEDICAL SOC
Inker, L A, Eneanya, N D, Coresh, J, Tighiouart, H, Wang, D, Sang, Y, Crews, D C, Doria, A, Estrella, M M, Froissart, M, Grams, M E, Greene, T, Grubb, A, Gudnason, V, Gutierrez, O M, Kalil, R, Karger, A B, Mauer, M, Navis, G, Nelson, R G, Poggio, E D, Rodby, R, Rossing, P, Rule, A D, Selvin, E, Seegmiller, J C, Shlipak, M G, Torres, V E, Yang, W, Ballew, S H, Couture, S J, Powe, N R, Levey, A S & Chronic Kidney Dis Epidemiology Co 2021, ' New Creatinine-and Cystatin C-Based Equations to Estimate GFR without Race ', New England Journal of Medicine, vol. 385, pp. 1737-1749 . https://doi.org/10.1056/NEJMoa2102953
The New England journal of medicine, vol 385, iss 19
New England Journal of Medicine, 385(19), 1737-1749. MASSACHUSETTS MEDICAL SOC
New Equations for Estimating GFR without Race Equations for estimating GFR with serum creatinine overestimate measured GFR in Blacks. The authors report new equations, without race as an inflation factor, using cystatin C and creatinine that reduced
Autor:
Niels Jongs, Douwe Postmus, Ricardo Correa-Rotter, David C. Wheeler, Claes Held, Tom Greene, Hiddo J.L. Heerspink, R D Toto, Anna Maria Langkilde, Johannes F.E. Mann, Fan Fan Hou, Investigators, Peter Rossing, C. David Sjöström, Glenn M. Chertow, John J.V. McMurray, Bergur V. Stefánsson
Publikováno v:
Circulation, 143(5), 438-448. LIPPINCOTT WILLIAMS & WILKINS
Background: Dapagliflozin reduces the risk of end-stage renal disease in patients with chronic kidney disease. We examined the relative risk of cardiovascular and renal events in these patients and the effect of dapagliflozin on either type of event,
Autor:
Tine W. Hansen, Simone Theilade, Signe Abitz Winther, Peter Rossing, Jens P. Goetze, Nete Tofte, Sørine Birkelund
Publikováno v:
Diabetes Care. 44:595-603
OBJECTIVE Few studies have compared midregional proatrial natriuretic peptide (MR-proANP) and N-terminal probrain natriuretic peptide (NT-proBNP). We compared their value as risk markers for all-cause mortality and cardiovascular (CV) and renal compl
Autor:
Stefan D. Anker, Aslam Amod, Luis M. Ruilope, Gerasimos Filippatos, Amer Joseph, Michel Marre, Bertram Pitt, Charlie Scott, Andrea Lage, Rajiv Agarwal, George L. Bakris, Peter Rossing
Publikováno v:
Rossing, P, Agarwal, R, Anker, S D, Filippatos, G, Pitt, B, Ruilope, L M, Amod, A, Marre, M, Joseph, A, Lage, A, Scott, C, Bakris, G L & the FIDELIO-DKD Investigators 2022, ' Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment : A subgroup analysis from the FIDELIO-DKD trial ', Diabetes, Obesity and Metabolism, vol. 24, no. 1, pp. 125-134 . https://doi.org/10.1111/dom.14558
Diabetes, Obesity and Metabolism
Diabetes, Obesity and Metabolism, Wiley, 2021, ⟨10.1111/dom.14558⟩
Diabetes, Obesity and Metabolism
Diabetes, Obesity and Metabolism, Wiley, 2021, ⟨10.1111/dom.14558⟩
Aims Finerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease and type 2 diabetes in the FIDELIO-DKD trial (NCT02540993). This exploratory subgroup analysis investigates the effect o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e510c2d9fbacfc8d63bdfb21efa8263b
https://curis.ku.dk/ws/files/290250428/Efficacy_and_safety_of_finerenone_in_patients_with_chronic_kidney_disease_and_type_2_diabetes_by_GLP_1RA_treatment.pdf
https://curis.ku.dk/ws/files/290250428/Efficacy_and_safety_of_finerenone_in_patients_with_chronic_kidney_disease_and_type_2_diabetes_by_GLP_1RA_treatment.pdf
Autor:
Joseph B. Margolick, Chi-yuan Hsu, Todd E. Pesavento, Bertram L. Kasiske, Vilmundur Gudnason, Andrew S. Levey, Runolfur Palsson, Hans-Henrik Parving, Matthew R. Weir, Lawrence A. Kingsley, Emilio D. Poggio, Sara J. Couture, Christina M. Wyatt, James Hellinger, Amy B. Karger, Peter Rossing, Steef J. Sinkeler, Margret B. Andresdottir, Alison G. Abraham, Tariq Shafi, Lesley A. Inker, Gerald J. Beck, Hrefna Gudmundsdottir, Hocine Tighiouart, Alessandro Doria, Roberto S. N. Kalil, Michael Mauer, Olafur S. Indridason, Jing M. Chen, Steven M. Wolinsky, Anna C. Porter, Tom Greene, Michael G. Shlipak, Gerjan Navis, Wendy S. Post, John H. Eckfeldt, Paul L. Kimmel, Jonathan J. Taliercio, Harold I. Feldman, Mallory D. Witt, Zipporah Krishnasami
Publikováno v:
American Journal of Kidney Diseases, 77(5), 673-683.e1. W B SAUNDERS CO-ELSEVIER INC
CKD-EPI GFR Collaborators 2021, ' A New Panel Estimated GFR, Including β2-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse Population ', American Journal of Kidney Diseases, vol. 77, no. 5, pp. 673-683 . https://doi.org/10.1053/j.ajkd.2020.11.005
CKD-EPI GFR Collaborators 2021, ' A New Panel Estimated GFR, Including β2-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse Population ', American Journal of Kidney Diseases, vol. 77, no. 5, pp. 673-683 . https://doi.org/10.1053/j.ajkd.2020.11.005
Rationale and Objective: Glomerular filtration rate (GFR) estimation based on creatinine and cystatin C (eGFRcr-cys) is more accurate than estimated GFR (eGFR) based on creatinine or cystatin C alone (eGFRcr or eGFRcys, respectively), but the inclusi
Autor:
J. S. Haw, Michael Mauer, Janet B. McGill, Jill P. Crandall, Bruce A. Perkins, Ruth S. Weinstock, Katherine R. Tuttle, Afshin Parsa, Tom Elliott, Peter Rossing, Amy B. Karger, Amisha Wallia, Cathie Spino, Mark E. Molitch, I. H. de Boer, Maryam Afkarian, David Z.I. Cherney, Sylvia E. Rosas, Irl B. Hirsch, Sarit Polsky, Allison B. Goldfine, Andrzej T. Galecki, Guillermo E. Umpierrez, Ronald J. Sigal, Marlon Pragnell, Ildiko Lingvay, M. L. Caramori, Rodica Pop-Busui, Ronnie Aronson, William N. Robiner, Chun Yi Wu, David M. Maahs, Peter A. Senior, Alessandro Doria
Publikováno v:
N Engl J Med
BACKGROUND: Higher serum urate levels are associated with an increased risk of diabetic kidney disease. Lowering of the serum urate level with allopurinol may slow the decrease in the glomerular filtration rate (GFR) in persons with type 1 diabetes a
Autor:
M.M.J. van Greevenbroek, Nordin M J Hanssen, Casper G. Schalkwijk, M Piazza, M. P. H. van de Waarenburg, Frederik Persson, P Hovind, H. H. Parving, Peter Rossing, Jean L.J.M. Scheijen, Coen D.A. Stehouwer
Publikováno v:
Diabetic Medicine
Diabetic Medicine, 38(9):14405. Wiley
Piazza, M, Hanssen, N M J, Persson, F, Scheijen, J L, van de Waarenburg, M P H, van Greevenbroek, M M J, Rossing, P, Hovind, P, Stehouwer, C D A, Parving, H H & Schalkwijk, C G 2021, ' Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria : An IRMA2 sub-study ', Diabetic Medicine, vol. 38, no. 9, e14405 . https://doi.org/10.1111/dme.14405
Diabetic medicine, 38(9):e14405. Wiley-Blackwell
Diabetic Medicine, 38(9):14405. Wiley
Piazza, M, Hanssen, N M J, Persson, F, Scheijen, J L, van de Waarenburg, M P H, van Greevenbroek, M M J, Rossing, P, Hovind, P, Stehouwer, C D A, Parving, H H & Schalkwijk, C G 2021, ' Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria : An IRMA2 sub-study ', Diabetic Medicine, vol. 38, no. 9, e14405 . https://doi.org/10.1111/dme.14405
Diabetic medicine, 38(9):e14405. Wiley-Blackwell
Aim: Angiotensin receptor blockers (ARBs) reduce vascular complications in diabetes independently of blood pressure. Experimental studies suggested that ARBs may restore the detoxifying enzyme glyoxalase 1, thereby lowering dicarbonyls such as methyl
Autor:
Jan Erik Henriksen, Stuart J. McGurnaghan, Peter Rossing, Helen M. Colhoun, Adam Hulman, Reimar W. Thomsen, Gregers S. Andersen, Dorte Vistisen, Frederik Persson, Marit E. Jørgensen
Publikováno v:
Vistisen, D, Andersen, G S, Hulman, A, McGurnaghan, S J, Colhoun, H M, Henriksen, J E, Thomsen, R W, Persson, F, Rossing, P & Jørgensen, M E 2021, ' Response to Comment on Vistisen et al. A validated prediction model for endstage kidney disease in type 1 diabetes. Diabetes care 2021;44:901–907 ', Diabetes Care, vol. 44, no. 6, pp. e140-e141 . https://doi.org/10.2337/dci21-0010
We would like to thank Ostergaard et al. (1) for their perspective on our article (2), which includes a suggestion for using lifetime prediction models to estimate disease-free life expectancy. The lifetime prediction models previously published are
Autor:
Viktor Rotbain Curovic, Frederik Persson, Hans-Henrik Parving, Simone Theilade, Tine W. Hansen, Nete Tofte, Anders Jorsal, Signe Abitz Winther, Peter Rossing, Lise Tarnow
Publikováno v:
Curovic, V R, Theilade, S, Winther, S A, Tofte, N, Tarnow, L, Jorsal, A, Parving, H-H, Persson, F, Hansen, T W & Rossing, P 2021, ' Visit-to-visit variability of clinical risk markers in relation to long-term complications in type 1 diabetes ', Diabetic Medicine, vol. 38, no. 5, 14459 . https://doi.org/10.1111/dme.14459
BACKGROUND Clinical characteristics such as HbA1c , systolic blood pressure (SBP), albuminuria and estimated glomerular filtration rate (eGFR) are important when treating type 1 diabetes. We investigated the variability in these measures as risk mark
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::935777feff212c6808862d9326e29b31
https://pure.au.dk/portal/da/publications/visittovisit-variability-of-clinical-risk-markers-in-relation-to-longterm-complications-in-type-1-diabetes(c3dae41a-529a-4929-b8eb-5ecc5926e329).html
https://pure.au.dk/portal/da/publications/visittovisit-variability-of-clinical-risk-markers-in-relation-to-longterm-complications-in-type-1-diabetes(c3dae41a-529a-4929-b8eb-5ecc5926e329).html
Publikováno v:
Persson, F, Borg, R & Rossing, P 2021, ' A narrative review of new treatment options for chronic kidney disease in type 2 diabetes ', Annals of Translational Medicine, vol. 9, no. 8, pp. 716-716 . https://doi.org/10.21037/atm-20-4841
Ann Transl Med
Ann Transl Med
Diabetic kidney disease is a frequent and costly complication to type 2 diabetes. After many years with a lack of successful trials there are now significant developments that will change treatment, guidelines and future outcome. Since the last two d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8475fb0a8739bbfccb6e217afec8c1a7
https://curis.ku.dk/portal/da/publications/a-narrative-review-of-new-treatment-options-for-chronic-kidney-disease-in-type-2-diabetes(33958300-6ce0-4df9-9baf-323ef45b8c44).html
https://curis.ku.dk/portal/da/publications/a-narrative-review-of-new-treatment-options-for-chronic-kidney-disease-in-type-2-diabetes(33958300-6ce0-4df9-9baf-323ef45b8c44).html